All In Biotech

Drug Trial Radar · NCT04551053

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

177

Actual

Start

May 26, 2021

Primary completion

Aug 16, 2023

Study completion Aug 21, 2024

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

Conditions

  • Myelofibrosis
  • Primary Myelofibrosis
  • Post Essential Thrombocythemia Myelofibrosis
  • Post Polycythemia Vera Myelofibrosis

Interventions

  • parsaclisibDrug

    parsaclisib will be administered QD orally

  • ruxolitinibDrug

    ruxolitinib will be administered BID orally

  • placeboDrug

    placebo will be administered QD orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving ≥25% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging (MRI) (or Computed Tomography [CT] Scan in Applicable Participants)Time frame: Baseline; Week 24

Locations

177 sites in 19 countries. Site status is shown where the registry gives one.

  • Sutter Health Alta Bates Summit Medical Center Absmc Alta Bates Summit Comprehensive Cancer Center

    Berkeley, California

  • CCARE

    Fresno, California

  • California Research Institute (Cri)

    Los Angeles, California

  • Emad Ibrahim Md Inc

    Redlands, California

  • Scripps Clinic

    San Diego, California

  • Coastal Integrated Cancer Care - Cicc

    San Luis Obispo, California

  • Stamford Hospital - Medical Oncology Hematology

    Stamford, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • Emory University

    Atlanta, Georgia

  • Augusta University - Medical College of Georgia

    Augusta, Georgia

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • University of Kansas Hospital Authority

    Westwood, Kansas

  • Tulane University

    New Orleans, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Midamerica Cancer Care

    Kansas City, Missouri

  • New Jersey Hematology Oncology Associates Llc

    Brick, New Jersey

  • Morristown Medical Center - Atlantic Health System

    Morristown, New Jersey

  • Westchester Medical Center Advanced Oncology

    Hawthorne, New York

  • Mount Sinai School of Medicine

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Advent Health Hendersonville Park Ridge Hospital Hendersonville

    Clyde, North Carolina

  • Duke Cancer Center

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health & Science University

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Baptist Cancer Center

    Memphis, Tennessee

  • Texas Oncology - Medical City Dallas

    Dallas, Texas

  • Texas Oncology - Baylor Sammons Cancer Center

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Renovatio Clinical

    Houston, Texas

  • Kelsey Seybold Clinic

    Houston, Texas

  • Providence Regional Medical Center Everett

    Everett, Washington

  • Hanusch-Krankenhaus Wiener Gebietskrankenkasse

    Vienna, Austria

  • A.Z. St.-Jan A.V.

    Bruges, Belgium

  • Jessa Ziekenhuis

    Hasselt, Belgium

  • AZ Delta

    Roeselare, Belgium

  • Chu Ucl Namur University Hospital Mont-Godinne

    Yvoir, Belgium

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.